In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week 24 with efficacy progressively increasing throughout the treatment ...
Asianet Newsable on MSN
CRVS stock surges pre-market after Corvus expands equity raise to $175 million
Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock ...
Clinical-stage biopharmaceutical company Corvus Pharmaceuticals (CRVS) priced an upsized underwritten public offering of .9M ...
Vanda Pharmaceuticals Inc. company and executive profile by Barron's. View the latest VNDA company infomation and executive bios.
The two-time U.S. Olympic gold medalist gymnast opens up about her skin condition, her fashion dos and don’ts for eczema, and ...
Corvus Pharmaceuticals, Inc. jumps 165% on Phase 1 soquelitinib atopic dermatitis data; learn key efficacy, funding, and ...
Children who have multiple food allergies (FAs) and allergies to milk and eggs are more likely to have early-onset atopic dermatitis (AD).
How do early-life exposures shape the infant skin microbiome and atopic dermatitis risk? New cohort data reveal key ...
Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being ...
Atopia Therapeutics SA has reported new preclinical in vivo efficacy data supporting the potential of ATP-R13 as a novel oral ...
Corvus Pharmaceuticals Inc. rolled out new positive data to prove its thesis on the value of blocking IL-2-inducible T-cell kinase in atopic dermatitis (AD), and the company’s first-in-class approach ...
A study published in Nutrition Reviews in November 2025 found evidence linking oral probiotics and synbiotics to improvements in atopic dermatitis (AD) symptoms. However, research for other skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback